TP53Mutations in Breast and Ovarian Cancer

Abstract

Breast and ovarian cancers are the second and fifth leading causes of cancer deaths among women. Both breast and ovarian cancers are highly heterogeneous and are presented with diverse morphology, natural history, and response to therapy. In recent years, international efforts have led to extensive molecular characterization of both breast and ovarian tumors and identified biologically and clinically relevant subtypes of the diseases based on these molecular features. The role of TP53 in tumor initiation and progression is context dependent, and abrogation of the TP53 pathway seems to be essential for the development of basal-like breast cancers and high-grade serous ovarian cancers. These subtypes of breast and ovarian cancer show several genomic similarities including high frequency of TP53 mutation, which seems to be an early, initiating, and driving alteration in these cancer subtypes.

Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity

“…No statistically significant difference was observed between the survival outcomes of the other cancer types harboring TP53 mutations (Supplemental Figure 1). For example, there was no survival difference when comparing TP53 mutations based on residual transcriptional activity in breast cancer, although it is well established that breast cancer patients with TP53 mutations have poorer outcomes compared with WT carriers (23,24). These findings might indicate that a TP53 mutation represents only 1 key factor in projecting survival in certain cancer types, which may also be subtype specific (25).…”

Long non-coding RNA FAM83H-AS1 acts as an oncogenic driver in human ovarian cancer

“…At last, we also constructed a lncRNA-mRNA ceRNA network (Figure 4D). TP53 was a ceRNA of FAM83H-AS1 and mutations in the TP53 gene are still by far the most frequent genomic event in cancer genomes [22]. All the results indicated that FAM83H-AS1 maybe play its role by interacting with some OC-related coding genes and 6 miRNAs.…”

Long non-coding RNA FAM83H-AS1 acts as an oncogenic driver in human ovarian cancer

“…At last, we also constructed a lncRNA-mRNA ceRNA network ( Figure 4D). TP53 was a ceRNA of FAM83H-AS1 and mutations in the TP53 gene are still by far the most frequent genomic event in cancer genomes [22]. All the results indicated that FAM83H-AS1 maybe play its role by interacting with some OC-related coding genes and miRNAs.…”